Cover Image
市場調查報告書

C型肝炎治療藥市場:2017年∼2027年的預測 - C型肝炎治療藥,直接作用型抗病毒藥物 (DAA),Ribavirin,蛋白分解酵素抑制劑,聚合酵素抑制劑,干擾素的收益預測

Hepatitis C Therapies Market 2017-2027: Revenue Forecasts for Hepatitis C Therapeutics, Direct-Acting Antivirals, Ribavirin, Protease Inhibitors, Polymerase Inhibitors, Interferons and R&D

出版商 Visiongain Ltd 商品編碼 320321
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎治療藥市場:2017年∼2027年的預測 - C型肝炎治療藥,直接作用型抗病毒藥物 (DAA),Ribavirin,蛋白分解酵素抑制劑,聚合酵素抑制劑,干擾素的收益預測 Hepatitis C Therapies Market 2017-2027: Revenue Forecasts for Hepatitis C Therapeutics, Direct-Acting Antivirals, Ribavirin, Protease Inhibitors, Polymerase Inhibitors, Interferons and R&D
出版日期: 2017年10月24日 內容資訊: 英文 180 Pages
簡介

C型肝炎治療藥市場的收益2016年達到190億美元,預計至2021年以1.7%的年複合成長率成長。

本報告提供全球C型肝炎治療藥市場相關調查分析,資料,趨勢,機會,多等級的銷售額預測等系統性資訊。

第1章 報告概要

第2章 C型肝炎治療藥的簡介

  • C型肝炎和治療藥概要
  • 遺傳基因型
  • 症狀:急性、慢性C型肝炎
  • C型肝炎的診斷:無症狀性
  • C型肝炎的危險因素
  • 發病率和盛行率的模式
  • C型肝炎:治療藥與預防
  • 抗病毒藥物:病毒的複製的阻礙
  • 干擾素:2個作用機制
  • C型肝炎和疫苗的需求

第3章 全球C型肝炎治療藥市場

  • C型肝炎治療藥市場
  • C型肝炎治療藥市場:收益預測
  • 意識的提高和篩檢:治療人口的增加
  • C型肝炎治療藥市場上非專利的競爭
  • 生物相似藥干擾素
  • 直接作用型抗病毒藥物 (DAA):治療形勢的變化
  • 口服抗病毒藥物的次市場
  • 口服抗病毒藥物的次市場:收益預測
  • 強力的開發平台促進市場成長
  • C型肝炎的全部的口服治療藥:耐容能力的提高
  • 干擾素的次市場
  • C型肝炎的標準治療等

第4章 主要國家的C型肝炎治療藥市場

  • 全球C型肝炎的盛行率
  • 亞洲的重要性
  • C型肝炎治療藥市場:各地區的明細
  • C型肝炎治療藥市場:各地區的預測
  • 美國
  • EU主要國家
  • 各地區的盛行率
  • EU5個國家
  • 亞洲
  • 中國
  • 日本
  • 印度
  • 俄羅斯
  • 巴西

第5章 主要C型肝炎治療藥:市場預測

  • 主要的C型肝炎治療藥
  • Harvoni (Gilead Sciences)
  • Sovaldi (Gilead Sciences)
  • Epclusa (Merck & Co.)
  • Daklinza (Bristol-Myers Squibb)
  • Zepatier (Merck & Co.)
  • Sunvepra (Bristol-Myers Squibb)
  • Pegasys (Roche)
  • PegIntron (Merck & Co.)
  • Olysio (Janssen/Medivir)

第6章 C型肝炎治療藥市場:主要的研發產品線候補藥

第7章 C型肝炎治療藥市場上主要企業

  • 主要的市場企業
  • Gilead Sciences
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Roche
  • Bristol-Myers Squibb
  • Merck & Co.
  • 主要的C型肝炎開發平台企業
  • Gilead Sciences
  • Merck & Co.
  • AbbVie (舊:Abbott Laboratories)
  • Achillion Pharmaceuticals

第8章 C型肝炎治療藥市場:產業趨勢

  • 全球C型肝炎治療藥、疫苗市場SWOT分析
  • 全球C型肝炎治療藥、疫苗市場STEP分析
  • C型肝炎疫苗
  • 口服直接作用型抗病毒藥物 (DAA)
  • 核甘、非核甘聚合酵素抑制劑
  • 蛋白分解酵素與聚合酵素阻礙藥物的組合
  • Ribavirin的必要性
  • 12週治療的目標
  • 對C型肝炎的醫藥品投資

第9章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0251

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 180-page report you will receive 67 tables and 50 figures- all unavailable elsewhere.

The 180-page report provides clear detailed insight into the Hepatits C Therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

The revenue of the Hepatitis C market in 2016 is estimated at $19bn and is expected to grow at a CAGR of 1.7% in the first half of the forecast period. Oral antivirals accounted for the largest share of the market in 2016, this segment generated $18.7bn.

Read on to discover how this definitive report can transform your own research and save you time.

The new market assessment benefits research, analysis and planning in seven main ways:

  • World HCV market revenue to 2027 - discover that industry's overall sales potential
  • Two product classes' revenues to 2027 - investigate categories at world level, finding the most lucrative and promising therapy classes
  • Eight leading drugs' revenues to 2027 - find sales predictions for top and emerging products, seeing how agents compete and succeed
  • 11 national markets in the Americas, Europe and Asia covered, with forecasts to 2027 - discover the best countries for trade expansion
  • Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances, collaborations and outlooks
  • R&D for antiviral medicines - investigate progress in that industry, exploring technological, clinical and commercial opportunities
  • Analysis of what stimulates and restrains that industry and market - assess challenges, strengths, competition and opportunities, helping you succeed.

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects For treating hepatitis C virus, our report shows you data, trends, opportunities and multilevel sales forecasts. So, avoid missing out. Instead please get that new analysis here now.

Report highlights

  • 192 pages, 67 tables and 50 figures
  • Hepatitis C Market Therapies Market Forecast from 2017 to 2027
  • This report also breaks down the revenue forecast for the main submarkets:
  • Oral Antivirals
  • Interferons
  • Analysis of the Oral Antivirals drugs market. Revenue forecasts to 2027 are provided for the following drugs:
  • Harvoni
  • Sovaldi
  • Epclusa
  • Daklinza
  • Analysis of the Interferons drugs market. Revenue forecasts to 2027 are provided for the following drugs:
  • Pegasys
  • PegIntron
  • Analysis of key players in Hepatitis C Therapeutics
  • Gilead Sciences
  • Merck and Co.
  • Roche
  • Bristol Myers Squibb
  • Janssen
  • Achillion Pharmaceuticals

image1

  • Regional Hepatitis C market forecasts from 2017-2027
  • US forecast 2017-2027,
  • China forecast 2017-2027
  • Japan forecast 2017-2027
  • India forecast 2017-2027
  • Germany forecast 2017-2027
  • UK forecast 2017-2027
  • France forecast 2017-2027
  • Brazil Forecast 2017-2027
  • Russia Forecast 2017-2027
  • Key questions answered
  • What does the future hold for the Hepatitis C Therapies industry?
  • Where should you target your business strategy?
  • What technologies give the most promising candidates for new drugs?
  • Which disruptive technologies should you invest in?
  • Which companies should you form strategic alliances with?
  • Which company is likely to success and why?
  • What business models should you adopt?
  • What industry trends should you be aware of?
  • Which is the company with the highest expected revenue from 2017 to 2027?
  • Where lie the best geographical opportunities for selling those antivirals?
  • Why will the HCV drug market expand, and what limits its sales growth?
  • How will companies overcome challenges in serving regulators, patients and payers?
  • Target audience
  • Leading Hepatitis C companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Industry organisations
  • Banks

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Hepatitis C Therapies
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by this Analysis
  • 1.5 Who is this Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Hepatitis C Therapies

  • 2.1 A Breif History of Hepatitis C and Treatments
  • 2.2 Genotypes
  • 2.3 Symptoms: Acute and Chronic Hepatitis C
  • 2.4 Diagnosing Hepatitis C: The Asymptomatic Nature
  • 2.5 Risk Factors for Hepatitis C
  • 2.6 Incidence and Prevalence Patterns
  • 2.7 Hepatitis C: Treatment and Prevention
  • 2.8 Antivirals: Inhibiting Virus Replication
    • 2.8.1 Protease Inhibitors
    • 2.8.2 Polymerase Inhibitors
    • 2.8.3 NS5A Replication Complex Inhibitors
  • 2.9 Interferons: Dual Mode of Action
    • 2.9.1 Combination Therapy: Treatment with Interferons and Antivirals
    • 2.9.2 Interferon-Free Regimens
  • 2.10 Hepatitis C and the Need for a Vaccine

3. The World Hepatitis C Therapies Market, 2017-2027

  • 3.1 Hepatitis C Therapies Market, 2015 and 2016
  • 3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2016-2027
  • 3.3 Rising Awareness and Screening: Expanding Treatment Population
  • 3.4 Generic Competition in the Hepatitis C Therapies Market
  • 3.5 Biosimilar Interferons
  • 3.6 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
  • 3.7 Oral Antivirals Submarket
  • 3.8 Oral Antivirals Submarket: Revenue Forecast, 2016-2027
  • 3.9 A Strong Developmental Pipeline to Drive Market Growth
  • 3.10 All-Oral Treatments for Hepatitis C: Improving Tolerability
  • 3.11 Interferons Submarket
  • 3.12 Standard of Care for Hepatitis C
  • 3.13 Drawbacks to Interferon Therapy
  • 3.14 Declining Revenues 2008-2016
  • 3.15 Interferons Submarket: Revenue Forecast, 2016-2027
  • 3.16 Next Generation Interferons: A Potential Advance or Lateral Move?
  • 3.17 Hepatitis C Vaccines Submarket
  • 3.18 Hepatitis C Therapies: Submarket Shares 2016, 2021 and 2027

4. Leading National Hepatitis C Markets, 2016-2027

  • 4.1 Global Prevalence of Hepatitis C, 2016
  • 4.2 The Importance of Asia
  • 4.3 Hepatitis C Therapies Market: Regional Breakdown, 2016
  • 4.4 Hepatitis C Therapies Market: Regional Forecast, 2016-2027
  • 4.5 US Hepatitis C Market
    • 4.5.1 Population Movement and Hepatitis C
    • 4.5.2 The Affordable Care Act and Hepatitis C
    • 4.5.3 Increased Screening towards Target Population
    • 4.5.4 The US Revenue Forecast, 2016-2027
  • 4.6 Leading EU Markets for Hepatitis C Therapies
  • 4.7 Regional Prevalence
  • 4.8 EU5 Hepatitis C Market, 2016
    • 4.8.1 EU5 Hepatitis C Market: Revenue Forecasts, 2016-2027
    • 4.8.2 Italy Hepatitis C Market: Revenue Forecasts, 2016-2027
    • 4.8.3 Spain Hepatitis C Market: Revenue Forecasts, 2016-2027
    • 4.8.4 Germany Hepatitis C Market: Revenue Forecasts, 2016-2027
    • 4.8.5 UK Hepatitis C Market: Revenue Forecasts, 2016-2027
    • 4.8.6 France Hepatitis C Market: Revenue Forecasts, 2016-2027
  • 4.9 Hepatitis C in Asia
  • 4.10 China Hepatitis C Market
    • 4.10.1 Decline in Incidence of Hepatitis C
    • 4.10.2 Rising Middle Class
    • 4.10.3 Hepatitis C Outbreaks
    • 4.10.4 Domestic Drug and Vaccine Development
    • 4.10.5 China: Revenue Forecast, 2016-2027
  • 4.11 Japan
    • 4.11.1 Hepatitis C in Japan
    • 4.11.2 Japan: Revenue Forecast, 2016-2027
  • 4.12 India
    • 4.12.1 Low Awareness Rates
    • 4.12.2 India: Revenue Forecast, 2016-2027
  • 4.13 Russia
    • 4.13.1 Low Treatment Rates and High Drug Cost Limiting Market
    • 4.13.2 Adverse Impact of Western Sanctions on Russian Pharma Market
    • 4.13.3 Russia: Revenue Forecast, 2016-2027
  • 4.14 Brazil
    • 4.14.1 Current Disease Prevalence
    • 4.14.2 Brazil: Revenue Forecast, 2016-2027

5. Leading Hepatitis C Therapies: Market Prospects 2016 to 2027

  • 5.1 Leading Hepatitis C Therapies, 2016-2027
  • 5.2 Harvoni (Gilead Sciences)
    • 5.2.1 Gilead-AbbVie Dispute over Ledipasvir/Sofosbuvir Patents
    • 5.2.2 Harvoni Revenue Forecast, 2016-2027
  • 5.3 Sovaldi (Gilead Sciences)
    • 5.3.1 Recent Revenue Analysis
    • 5.3.2 Gilead Licenses Generic Substitute for Sovaldi for Production and Sales in Developing Countries
    • 5.3.3 Sovaldi Revenue Forecast, 2016-2027
  • 5.4 Epclusa (Merck & Co.)
    • 5.4.1 Epclusa: Revenue Forecast, 2016-2027
  • 5.5 Daklinza (Bristol-Myers Squibb)
    • 5.5.1 Daklinza Revenue Forecast, 2016-2027
  • 5.6 Zepatier (Merck & Co.)
    • 5.6.1 Zepatier Revenue Forecast, 2016-2027
  • 5.7 Sunvepra (Bristol-Myers Squibb)
    • 5.7.1 Sunvepra: Synergistic Effect with Daklinza
    • 5.7.2 Sunvepra Revenue Forecast, 2016-2027
  • 5.8 Pegasys (Roche)
    • 5.8.1 Recent Revenue Analysis
    • 5.8.2 Label Expansions and Lifecycle Management Strategies
    • 5.8.3 Pegasys Revenue Forecast, 2016-2027
  • 5.9 PegIntron (Merck & Co.)
    • 5.9.1 Recent Revenue Analysis
    • 5.9.2 Competition from Interferon Biosimilars
    • 5.9.3 Enhancing Drug Life Cycle
    • 5.9.4 PegIntron Revenue Forecast, 2016-2027
  • 5.10 Olysio (Janssen/Medivir)
    • 5.10.1 Recent Revenue Analysis
    • 5.10.2 Combination Regimen of Sovaldi and Olysio
    • 5.10.3 Olysio Revenue Forecast, 2016-2027

6. Hepatitis C Therapies Market: Leading R&D Pipeline Candidates, 2016

  • 6.1 Introduction to Hepatitis C Therapy Candidates
  • 6.2 Glecaprevir/Pibrentasvir (Abbvie)
  • 6.3 Sofosbuvir/Velpatasvir/Voxilaprevir (Gilead Sciences)
  • 6.4 Uprifosbuvir/Grazoprevir/Ruzasvir (Merck and Co.)
  • 6.5 AL-335/Odalasvir/Simeprevir (Achillion and Janssen)
  • 6.6 Protease Inhibitors Pipeline
    • 6.6.1 Sovaprevir (Achillion Pharmaceuticals): Playing Catch Up
    • 6.6.2 Danoprevir (Roche): Testing Out Combination Regimens
    • 6.6.3 Lomibuvir (Vertex Pharmaceuticals)
    • 6.6.4 ABT-493 (AbbVie)
    • 6.6.5 GS-9857 (Gilead Sciences)
  • 6.7 Polymerase Inhibitors Pipeline
    • 6.7.1 ACH-2928 (Achillion Pharmaceuticals)
    • 6.7.2 BMS-791325 (Bristol-Myers Squibb): Phase II
    • 6.7.3 TMC-647055 (Janssen): Phase II
    • 6.7.4 Mercitabine (Roche/Pharmasset): Broad Spectrum Treatment
    • 6.7.5 Setrobuvir (Roche): Non-Nucleoside Inhibitor
    • 6.7.6 VX-135 (Vertex Pharmaceuticals): Interferon- and Ribavirin-Free Regimens
    • 6.7.7 GS-9669 (Gilead Sciences)
    • 6.7.8 PPI-383 (Presidio Pharmaceuticals)
  • 6.8 NS5A Inhibitors Pipeline
    • 6.8.1 ABT-530 (AbbVie)
    • 6.8.2 Samatisvir (Merck & Co.): Acquired from Idenix
    • 6.8.3 GS-5816 (Gilead Sciences)
    • 6.8.4 PPI-668 (Presidio Pharmaceuticals)
    • 6.9 Interferon Pipeline
    • 6.9.1 Locteron (Biolex): Controlled Release Formulation
    • 6.9.2 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effects Profile
  • 6.10 Novel Inhibitors
    • 6.10.1 SCY-635 (SCYNEXIS)
    • 6.10.2 Miraversen (Santaris)
    • 6.10.3 GS-9620 (Gilead Sciences)
    • 6.10.4 RG-101 (Regulus Therapeutics)
    • 6.10.5 Leading Hepatitis C Vaccine Pipeline Candidates, 2017
    • 6.10.6 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
    • 6.10.7 GI-5005 (GlobeImmune): Yeast-Based Hepatitis C Vaccine
    • 6.10.8 INO-8000 HCV (Inovio Pharmaceuticals): Therapeutic Vaccine in Phase I Trials
    • 6.10.9 Okairos Inc.: Prophylactic and Therapeutic Vaccine Candidates

7. Leading Companies in the Hepatitis C Therapies Market

  • 7.1 Leading Market Players, 2015 and 2016
  • 7.2 Gilead Sciences
    • 7.2.1 Product Overview and Performance, 2015 and 2016
    • 7.2.2 Recent Developments: Gilead Sciences Acquires Pharmasset
    • 7.2.3 Hepatitis Pipeline: Strong and Diverse
    • 7.2.4 Future Outlook: Strongest Pipeline than Any Other Company
  • 7.3 Johnson & Johnson (Janssen Pharmaceuticals)
    • 7.3.1 Product Overview and Performance, 2015 and 2016
    • 7.3.2 Recent Developments: Acquisition of Alios BioPharma
    • 7.3.3 Hepatitis Pipeline
    • 7.3.4 Future Outlook: Combination Regimens with Olysio
  • 7.4 Roche
    • 7.4.1 Product Overview and Performance, 2015 and 2016
    • 7.4.2 Recent Developments: Partnership with Anadys
    • 7.4.3 Hepatitis Pipeline
    • 7.4.4 Future Outlook: Slowing Demand May Affect Market Dominance
  • 7.5 Bristol-Myers Squibb
    • 7.5.1 Product Overview and Performance, 2015 and 2016
    • 7.5.2 Recent Developments: Strengthening Product Pipeline Through Acquisitions
    • 7.5.2.1 Bristol-Myers Squibb Acquires Inhibitex
    • 7.5.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
    • 7.5.4 Future Outlook: Market Set For Intense Competition
  • 7.6 Merck & Co.
    • 7.6.1 Product Overview and Performance, 2015 and 2016
    • 7.6.2 Recent Developments: Merck & Co. Acquires Idenix
    • 7.6.3 Hepatitis Pipeline
    • 7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
  • 7.7 Leading Hepatitis C Pipeline Companies, 2017
  • 7.8 Gilead Sciences
  • 7.9 Merck & Co.
  • 7.10 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
  • 7.11 Achillion Pharmaceuticals: Next Target for Acquisition
    • 7.11.1 Achillion and Gilead
    • 7.11.2 Achillion and Janssen

8. Hepatitis C Therapies Market: Industry Trends, 2016-2027

  • 8.1 SWOT Analysis of the World Hepatitis C Therapies and Vaccines Market, 2016-2027
    • 8.1.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2016-2027
      • 8.1.1.1 Interferon Therapy Has Drawbacks
      • 8.1.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
    • 8.1.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2016-2027
      • 8.1.2.1 Hepatitis Screening and Diagnosis
      • 8.1.2.2 Raising Awareness and Overcoming Social Stigma
      • 8.1.2.3 Personalised Therapy
      • 8.1.2.4 HIV Co-Infection
      • 8.1.2.5 Asia
  • 8.2 STEP Analysis of the World Hepatitis C Therapies and Vaccines Market, 2016-2027
    • 8.2.1 Social Development
      • 8.2.1.1 Social Implications in China
    • 8.2.2 Technological Advances
    • 8.2.3 Economic Pressures
    • 8.2.4 Political Issues
  • 8.3 Hepatitis C Vaccines
  • 8.4 Oral Direct-Acting Antivirals
  • 8.5 Nucleoside and Non-Nucleoside Polymerase Inhibitors
  • 8.6 Combining Protease and Polymerase Inhibitors
  • 8.7 The Need for Ribavirin
  • 8.8 Twelve-Week Treatment Target
  • 8.9 Pharmaceutical Investment in Hepatitis C
    • 8.9.1 Licensing and Partnering Deals
    • 8.9.2 Acquisitions in Hepatitis C
    • 8.9.3 Other Companies of Note for Hepatitis Treatment Developments

9. Conclusions

  • 9.1 State of the Hepatitis C Therapies Market, 2016 and 2017
  • 9.2 Growth in the Hepatitis C Therapies Market, 2016-2027
    • 9.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
    • 9.2.2 Asia as a Hepatitis C Drug Market
  • 9.3 Concluding Remarks

Associated Visiongain Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 Submarket Forecasts of Hepatitis C Therapies, 2016-2027
  • Table 2.1 Global Pattern of Hepatitis C Genotypes and Subtypes, 2016
  • Table 2.2 Approved Antiviral Subtypes for Hepatitis C, 2016
  • Table 3.1 Hepatitis C Therapies Market ($mn) by Sector and Market Share (%) 2015
  • Table 3.2 Hepatitis C Therapies Market ($mn) and Market Share (%) by Sector, 2016
  • Table 3.3 Hepatitis C Therapies Market: Overall Market Forecast of Currently Approved Drugs and Predicted Approvals ($mn), AGR (%) and CAGR (%), 2016-2027
  • Table 3.4 Hepatitis C Therapies Market: Revenue Forecasts by Segment ($mn), AGR (%) and CAGR (%), 2016-2027
  • Table 3.5 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging National Markets, 2016
  • Table 3.6 Leading Hepatitis C Antivirals: Revenue Shares by Drug ($mn) and Market Share (%), 2016
  • Table 3.7 Oral Antivirals Submarket: Revenue Forecast ($mn), AGR (%) and CAGR (%), 2016-2027
  • Table 3.8 Interferons Submarket: Revenue ($mn) and Market Share (%) by Drug, 2016
  • Table 3.9 Interferons Submarket: Revenue Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 3.10 Hepatitis C Submarket Shares (%), 2016, 2021 & 2027
  • Table 4.1 Global Prevalence of Chronic
  • Table 4.2 Hepatitis C Therapies: Revenue ($mn) and Market Share (%) by Region, 2016
  • Table 4.3 Hepatitis C Therapies: Overall Market and Revenue Forecasts ($mn) by Region, AGR (%) and CAGR (%) 2016-2027
  • Table 4.4 US Hepatitis C Therapies Market: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.5 EU5 Hepatitis C Therapies Revenue ($mn), EU5 Market Share (%) and Global Market Share (%) by Country, 2016
  • Table 4.6 EU5 Hepatitis C Therapies Market: Overall Revenue Forecasts ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.7 Italian Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.8 Spanish Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.9 German Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.10 UK Hepatitis C Therapies: Forecast ($mn), ARG (%) and CAGR (%) 2016-2027
  • Table 4.11 French Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.12 Chinese Hepatitis C Therapies: Forecast ($mn), 2016-2027
  • Table 4.13 Japanese Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.14 Indian Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.15 Russian Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 4.16 Brazilian Hepatitis C Therapies: Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 5.1 Selected Leading Hepatitis C Therapies ($mn) and Market Share (%), 2016
  • Table 5.2 Harvoni: Key Facts, 2017
  • Table 5.3 Harvoni: Revenue Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 5.4 Sovaldi: Key Facts, 2017
  • Table 5.5 Sovaldi: Revenue ($mn) by Region, Q1-Q2 2017
  • Table 5.6 Sovaldi: Revenue Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 5.7 Epclusa: Key Facts, 2017
  • Table 5.8 Epclusa: Revenue Forecast ($mn), AGR (%) and CAGR (%) B2016-2027
  • Table 5.9 Daklinza: Key Facts, 2017
  • Table 5.10 Daklinza: Revenue Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 5.11 Zepatier: Key Facts, 2017
  • Table 5.12 Zepatier: Revenue Forecast ($mn), AGR and CAGR (%) and 2016-2027
  • Table 5.13 Sunvepra: Key Facts, 2017
  • Table 5.14 Sunvepra: Revenue Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 5.15 Pegasys: Key Facts, 2017
  • Table 5.16 Pegasys: Revenue Forecast ($mn), AGR (%) and CAGR (%) 2016-2027
  • Table 5.17 PegIntron: Key Facts, 2017
  • Table 5.18 PegIntron: Revenue Forecast ($mn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.19 Olysio: Key Facts, 2017
  • Table 5.20 Olysio: Revenue ($mn) by Region, Q1-Q2 2017
  • Table 5.21 Olysio: Revenue Forecast ($mn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1 Hepatitis C Therapies: Revenue ($mn) and Market Share (%) by Company, 2015
  • Table 7.2 Hepatitis C Therapies: Revenue ($mn) and Market Share (%) by Company, 2016
  • Table 7.3 Gilead Sciences: Revenue ($mn) and Revenue Share (%) by Therapeutic Area, 2016
  • Table 7.4 Gilead Sciences: Hepatitis C Pipeline, 2016
  • Table 7.5 Roche: Hepatitis C Pipeline, 2016
  • Table 7.6 Pegasys: Revenue ($mn) and Market Share (%), 2016, 2021 & 2027
  • Table 7.7 Bristol-Myers Squibb: Hepatitis Pipeline, 2016
  • Table 7.8 Merck & Co: Pharmaceutical Revenue ($mn) and Revenue Share (%) by Therapeutic Area, 2016
  • Table 7.9 Gilead Sciences: Hepatitis C All-Oral Regimens, 2016
  • Table 7.10 Merck & Co.: Hepatitis C All-Oral Regimens, 2016
  • Table 7.11 AbbVie: Hepatitis C All-Oral Regimens, 2016
  • Table 7.12 Achillion Pharmaceuticals: Hepatitis C All-Oral Regimens, 2016
  • Table 8.1 Hepatitis C Therapies Market: Strengths and Weaknesses, 2016
  • Table 8.2 Hepatitis C Therapies Market: Opportunities and Threats, 2016-2027
  • Table 8.3 Liver Cancer: Deaths by Region, 2016
  • Table 9.1 Hepatitis C Therapies: Revenue ($mn) by Drug and Segment, 2016, 2021 & 2027
  • Table 9.2 Leading Hepatitis C Therapies: Patent Expiries and Peak Revenues ($mn)

List of Figures

  • Figure 2.1 A Brief History of Hepatitis, 1947-2016
  • Figure 3.1 Hepatitis C Therapies Market by Segment (%), 2015
  • Figure 3.2 Hepatitis C Therapies Market by Segment (%), 2016
  • Figure 3.3 Hepatitis C Therapies Market: Overall Market Forecast ($mn), 2016-2027
  • Figure 3.4 Global Hepatitis C Therapies Market: Drivers and Restraints, 2016-2027
  • Figure 3.5 Leading Hepatitis C Antivirals Submarket Share (%), 2016
  • Figure 3.6 Oral Antivirals Market: Drivers and Restraints, 2016-2027
  • Figure 3.7 Oral Antivirals Submarket: Revenue Forecast ($mn), 2016-2027
  • Figure 3.8 Interferons Submarket: Market Share (%) by Drug, 2016
  • Figure 3.9 Interferons Submarket: Revenue Forecast ($mn), 2016-2027
  • Figure 3.10 Interferons Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.11 Hepatitis C Submarket Shares ($mn), 2016, 2021 & 2027
  • Figure 4.1 Chronic Hepatitis C: Global Prevalence (%) by Region, 2016
  • Figure 4.2 Hepatitis C Therapies: Market Share (%) by Region, 2016
  • Figure 4.3 Hepatitis C Therapies: Market Share (%) by Region, 2021
  • Figure 4.4 Hepatitis C Therapies: Market Share (%) by Region, 2027
  • Figure 4.5 US Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.6 EU5 Hepatitis C Therapies: Market Share (%) by Country, 2016
  • Figure 4.7 EU5 Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.8 Italian Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.9 Spanish Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.10 German Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.11 UK Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.12 French Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.13 Chinese Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.14 Japanese Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.15 Indian Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.16 Russian Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 4.17 Brazilian Hepatitis C Therapies: Submarket Forecast ($mn), 2016-2027
  • Figure 5.1 Harvoni: Revenue Forecast (mn), 2016-2027
  • Figure 5.2 Sovaldi: Revenue ($mn) by Region, Q1-Q2, 2017
  • Figure 5.3 Sovaldi: Revenue Forecast ($mn), 2016-2027
  • Figure 5.4 Epclusa: Revenue Forecast ($mn), 2016-2027
  • Figure 5.5 Daklinza: Revenue Forecast ($mn), 2016-2027
  • Figure 5.6 Zepatier: Revenue Forecast ($mn), 2016-2027
  • Figure 5.7 Sunvepra: Revenue Forecast ($mn), 2016-2027
  • Figure 5.8 Pegasys: Historical Revenue ($mn), 2011-2016
  • Figure 5.9 Pegasys: Revenue Forecast ($mn), 2016-2027
  • Figure 5.10 PegIntron: Recent Revenue ($mn), 2013-2017
  • Figure 5.11 PegIntron: Revenue Forecast ($mn), 2016-2027
  • Figure 5.12 Olysio: Recent Revenue ($mn), US and ROW, Q1-Q2, 2017
  • Figure 5.13 Olysio: Revenue Forecast ($mn), 2016-2027
  • Figure 7.1 Hepatitis C Therapies: Market Share (%) by Company, 2015
  • Figure 7.2 Hepatitis C Therapies: Market Share (%) by Company, 2016
  • Figure 7.3 Gilead Sciences: Revenue Share (%) by Therapeutic Area, 2016
  • Figure 7.4 Johnson & Johnson: Key Events in the Hepatitis C Drug Market, 2011-2016
  • Figure 7.5 Pegasys: Revenue ($mn), 2016, 2021 & 2027
  • Figure 7.6 Merck & Co: Revenue Share (%) by Therapeutic Area, 2016
  • Figure 8.1 Liver Cancer: Deaths by Region, 2016
  • Figure 9.1 Hepatitis C Therapies: Revenue ($mn) by Segment, 2016, 2021 & 2027

Companies Listed

  • 3S Bio
  • Abbvie
  • Achillion Pharmaceuticals
  • Alios BioPharma
  • Amega Biotech
  • Anadys
  • Biolex
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cadila Healthcare
  • Chinese State Food and Drug Administration (SFDA)
  • ChronTech Pharma
  • Cipla
  • European Medicines Agency (EMA)
  • Feron
  • Food and Drug Administration (FDA)
  • Gets Pharma
  • Gilead Sciences
  • GlobeImmune
  • Hetero abs
  • Hualida Biotech
  • Idenix
  • Inhibitex
  • Inovio Pharmaceuticals
  • Intas Biopharmaceuticals
  • Janssen
  • Japanese Ministry of Health, Labour and Welfare (JMHLW)
  • LG Life Sciences
  • Medivir
  • Merck and Co.
  • Mylan Laboratories
  • National Health Service (NHS)
  • National Institute for Health and Clinical Excellence (NICE)
  • Okairos Inc
  • Pharmasset
  • PharmStandard
  • Presidio Pharmaceuticals
  • Probiomed
  • Ranbaxy Laboratories
  • Regulus Therapeutics
  • Reliance Life Sciences
  • Roche
  • Santaris
  • Sequent Scientific
  • Strides Acrolabs
  • The European Centre for Disease Control and Prevention
  • Vertex Pharmaceuticals
  • World Health Organisation (WHO)
Back to Top